A phase I/II study of PTK787 [vatalanib] in combination with trastuzumab in patients with newly diagnosed HER2 overexpressing locally recurrent or metastatic breast cancer: Hoosier Oncology Group Trial BRE04-80

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vatalanib (Primary) ; Trastuzumab
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Nov 2007 Patient numbers amended from 37 to 7
01 Nov 2007 Status changed from in progress to suspended.
27 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight